NextFin News - U.S. President Trump signed an executive order on Saturday, April 18, 2026, directing federal agencies to expedite the review and approval of psychedelic-based medical treatments, marking a significant shift in federal drug policy. The order specifically targets compounds like ibogaine, a potent psychedelic that has gained traction among veterans' groups for its potential to treat post-traumatic stress disorder (PTSD) and opioid addiction. Alongside the regulatory push, the administration committed $50 million in federal funding for research into ibogaine, signaling a move to integrate these once-stigmatized substances into the mainstream healthcare system.
The signing ceremony at the White House featured a notable coalition of supporters, including Robert F. Kennedy Jr. and media personality Joe Rogan, who reportedly advocated for the reform. The executive order instructs the Food and Drug Administration (FDA) and the Drug Enforcement Administration (DEA) to reduce "red tape" and establish a clear pathway for eligible patients to access these treatments under the Right to Try Act. This legislation allows terminally ill or severely afflicted patients to use investigational drugs that have passed early-stage clinical trials but lack full FDA approval. By prioritizing drugs with "Breakthrough Therapy" designations, the administration aims to bypass the decade-long timelines typical of psychiatric drug development.
Market reaction to the policy shift has been swift, with shares of psychedelic-focused biotech firms—often referred to as "shroom stocks"—trading higher in anticipation of the formal signing. Investors are betting that federal backing will de-risk a sector that has long struggled with the legal ambiguity of Schedule I classifications. However, the enthusiasm is not universal. Some public health experts caution that the rapid acceleration of these treatments could bypass critical safety evaluations. Ibogaine, in particular, has been linked to cardiac risks in some clinical settings, leading to concerns that a "fast-track" approach might overlook long-term side effects in favor of immediate political or social wins.
The move represents a rare alignment between the Trump administration’s deregulation agenda and a growing bipartisan interest in mental health reform. By framing the issue through the lens of the veteran suicide crisis and the opioid epidemic, U.S. President Trump has managed to pivot a traditionally counter-cultural movement into a pillar of his "America First" healthcare strategy. The Department of Health and Human Services (HHS) is now tasked with collaborating with the Department of Veterans Affairs to generate real-world evidence, a move that could eventually lead to the rescheduling of these substances under the Controlled Substances Act.
Despite the administrative momentum, the path to widespread clinical use remains fraught with logistical hurdles. The DEA still maintains strict handling authorizations for Schedule I substances, and the executive order’s success will depend on how quickly these two agencies can synchronize their oversight. While the $50 million research grant is a substantial federal endorsement, it remains a fraction of the capital required to bring a new drug to market. The pharmaceutical industry’s willingness to invest heavily in non-patentable natural compounds also remains a point of contention among analysts, who suggest that the real winners may be specialized clinics rather than traditional drug manufacturers.
Explore more exclusive insights at nextfin.ai.
